La cadena de opciones muestra datos clave de las opciones de acciones de Sharps Technology a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Sharps Technology..

Sharps Technology (NASDAQ:STSS) Bolsa, Cadena de Opciones

Sharps Technology

Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.

Boeing

Pre-Market Outlook

LGCB

STSS

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: LGCB, STSS, IX, QSI y BA.

5 acciones en el foco este lunes: LGCB, STSS, IX, QSI y BA

Movimiento de acciones

News

Markets

Movers

Trading Ideas

AEHL

ASYS

EFXT

GNFT

HYFM

LFVN

MTUS

RSLS

RVSB

SUNE

VEEE

VERO

WHLR

ReShape Lifesciences firma acuerdo exclusivo con Motion Informatics y dispara sus acciones antes de la apertura de mercado.

Acciones de ReShape Lifesciences (RSLS) se disparan un 82%; Aquí están 20 acciones que se mueven en premercado

Sportsman'sSaratoga,Springs,,Utah,,Usa,-,Nov,30,,2024:,Sportsman's,Warehouse

AGMH

BIAF

DGLY

GRFS

NCNO

NMAX

QUAD

RAPP

SAMG

SBFM

SPWH

SYRA

Sportsman&#39;s Warehouse sorprende con ingresos y ganancias inesperadas: conoce las cifras que hicieron subir sus acciones.

Acciones de Sportsman&#39;s Warehouse (SPWH) se disparan un 39%; Aquí están 20 acciones moviéndose en premercado

Barclays analyst Tom O'Malley maintains Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) with a Equal-Weight and raises the price target from $70 to $90.

Price Target

Analyst Ratings

QRVO

Barclays Maintains Equal-Weight on Qorvo, Raises Price Target to $90

&nbsp;Canaan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) ("Canaan" or the "Company"), an innovator in crypto mining, today announced that it has adopted a Cryptocurrency Holding Policy (the "Policy").&nbsp; The Policy establishes a clear and disciplined framework for the acquisition, custody, and disposition of cryptocurrencies, ensuring that such holdings are managed in a manner that supports the Company's liquidity needs, risk tolerance, and long-term strategic objectives.
Under the Policy, bitcoin is designated as the Company's primary long-term reserve asset. Unless required for liquidity management or risk mitigation, bitcoin accumulated through ordinary business activities—including self-mining and the sale of mining equipment—will generally be retained on a long-term basis. Canaan believes that a disciplined, long-term BTC reserve position fortifies its balance sheet, aligns the Company with the broader digital asset economy, and provides strategic optionality for future growth.
From time to time, Canaan may acquire other cryptocurrencies such as Ethereum or U.S. Genius Act–compliant stablecoins in the ordinary course of business. These non-core holdings will generally be converted into fiat currency, but they may also be held on a short- to medium-term basis when such positions directly support operational requirements, hedging strategies, or other approved corporate objectives.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Canaan Adopts Bitcoin-Focused Holding Policy To Strengthen Balance Sheet And Align With Digital Asset Strategy

Castor Maritime Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRM#NASDAQ">CTRM</a>), ("Castor" or the "Company"), a diversified global shipping and energy company, announces that on July 29, 2025, it successfully completed a sale and leaseback transaction for the M/V Magic Thunder, a 2011-built Kamsarmax bulk carrier vessel with a Japanese counterparty.
The bareboat financing amounts to $14.6 million, has a duration of five years, and a purchase option for the Company, beginning at the end of the second year of the bareboat charter period.

Asset Sales

CTRM

Castor Maritime Completes $14.6M Sale And Leaseback Deal For M/V Magic Thunder Bulk Carrier

Keybanc analyst Matthew Gillmor maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $400 to $350.

Keybanc Maintains Overweight on UnitedHealth Group, Lowers Price Target to $350

Barclays analyst Gaurav Jain maintains Philip Morris Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) with a Overweight and lowers the price target from $225 to $220.

Barclays Maintains Overweight on Philip Morris Intl, Lowers Price Target to $220

Barclays analyst Brandon Oglenski maintains Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) with a Overweight and raises the price target from $290 to $300.

Barclays Maintains Overweight on Norfolk Southern, Raises Price Target to $300

Keybanc analyst Justin Patterson maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Overweight and lowers the price target from $860 to $830.

SPOT

Keybanc Maintains Overweight on Spotify Technology, Lowers Price Target to $830

<ul>
<li>UNH</li>
<li>SOFI</li>
<li>GLD</li>
<li>AMD</li>
<li>NVDA</li>
<li>META</li>
<li>HOOD</li>
<li>AAPL</li>
<li>TSLA</li>
<li>NVO</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

HOOD

NVDA

SOFI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of July 30, 2025 (Via Swaggy Stocks)

Barclays analyst George Wang maintains Logitech International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) with a Overweight and raises the price target from $92 to $107.

LOGI

Barclays Maintains Overweight on Logitech International, Raises Price Target to $107

The Learning Cities of the Future: The APA enables the growth plans for the enlarged group to be accelerated, with the group's hi-tech, hi-touch Genius Resort and Genius City model of developing learning communities, to create the learning cities of the future.
Genius Resort Model: The group has an internal goal of launching 20 Genius Resorts within the next five years, providing retreats, accelerators and co-working on the ABCs to the Future (AI, Bitcoin, Community) in paradise locations, each with an average revenue goal of $5 million.
Genius City Model: The group has an internal goal of launching 100 licensed Genius Cities within the next five years, providing AI powered lifelong learning schools from early learning to student apprenticeships to adult mentoring, each with an average revenue goal of $1 million, and to build 5 owner managed Genius Cities, each with an average revenue goal of $20 million (All goals are intended and are not projections or forecasts).
Acceleration of Genius City Plan: Following the GNS ERL APA completion, the group will accelerate plans for the first $20 million model of Genius City, with the first fully developed Genius City Model in Bali, Indonesia.
2025 GNS Revenue Guidance: At the time of the announcement of the APA on June 10, 2025, Genius Group increased its revenue guidance for 2025 by 50% from $10 million to $15 million - $18 million as a result of the APA.
Education and Hospitality Expertise: While Genius Group's Genius Academy is built on an AI powered gamified learning platform, led by an expert Edtech team, Genius Resorts is building learning communities led by expert education and hospitality teams.
The Post APA plan includes further details of the Genius Resort and Genius Cities model, together with future plans, ERL financials and disclosures on related parties. The presentation, together with a link to the recording, can be viewed at <a href="https://www.globenewswire.com/Tracker?data=I4UgJFy_A5kbkbYaMx8KJUDuSyEZGp2WknXHVd_50mLXEEdJP4Q6RRD8NJxaNqshAArSblt8ZaxDVaO_8AzNGVMeOr6EePr8MKv-5Vi5o657ZMs3rqCvG8bjAeybyzkrHpT3K-px7ulOoLyzJl5Cuw==">https://investors.entrepreneurresorts.com/</a>.
Genius Group endorses ERL's Post APA plan and reaffirms the 50% increase in its revenue guidance for 2025 by 50% from $10 million to $15 million - $18 million, and may provide updated metrics as reintegration plans progress.

Guidance

Genius Group Reaffirms FY25 Increase In Its Revenue Guidance By 50% From $10M To $15M-$18M As A Result Of The APA

Barclays analyst Julian Mitchell maintains Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) with a Equal-Weight and raises the price target from $100 to $101.

Barclays Maintains Equal-Weight on Johnson Controls Intl, Raises Price Target to $101

Keybanc analyst Aleksey Yefremov maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Overweight and lowers the price target from $32 to $31.

Keybanc Maintains Overweight on Olin, Lowers Price Target to $31

British pharmaceutical giant GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 guidance. 
Driven by exceptional growth in Specialty Medicines and Vaccines, GSK&#8217;s second-quarter sales reached $10.66 billion (7.98 billion British pounds), a 6% increase at constant currency, exceeding <a href="https://www.benzinga.com/calendars/earnings">analyst estimates of $10.33 billion</a>.
Core earnings jumped 15% at constant currency to $1.24 per share (46.5 pence) outperforming the consensus forecast of $1.12.
Also Read: <a href="https://www.benzinga.com/news/health-care/25/07/46664599/gsk-merck-chinese-biotech-hengrui-pharma-collaborates" target="_blank" rel="noreferrer noopener">After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact</a>
The company attributed this core earnings growth to the strong performance of its Specialty Medicines and Vaccines divisions, coupled with higher royalty income and a disciplined escalation of investment in key research and development (R&amp;D) areas, particularly within Oncology and Vaccines.
Vaccine sales jumped 5% (+9% at constant currency or cc) to 2.09 billion pounds, reflecting growth in Meningitis vaccines related to uptake following expanded recommendation and public funding of Bexsero in Europe, as well as growth in Shingrix driven by launch uptake in France and strong demand across several other European markets and Japan.
Arexvy sales reached 66 million pounds, up 6% (+13% cc). Meningitis vaccine <a href="https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-continued-strong-performance/" target="_blank" rel="noreferrer noopener">sales</a> increased 17% (+22% cc) to 379 million, while established vaccine sales of 787 million increased 2% (+6% cc). <a href="https://www.benzinga.com/25/04/44634572/gsk-stock-is-trading-higher-as-new-study-shows-shingles-vaccine-linked-to-20-lower-dementia-risk" target="_blank" rel="noreferrer noopener">Shingrix sales</a> reached 853 million pounds, up 3% (+6% cc).
In July, the FDA agreed to review the application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46423319/gsk-seeks-fda-nod-to-broaden-rsv-vaccine-for-younger-at-risk-adults" rel="noreferrer noopener">who are at increased risk</a>.
Also in July, the FDA extended the review period for the Biologics License Application (BLA) for GSK&#8217;s Blenrep combinations for relapsed or refractory multiple myeloma patients who have received at <a href="https://www.benzinga.com/news/fda/25/07/46607015/gsks-blood-cancer-drug-review-extended-as-fda-seeks-more-data" target="_blank" rel="noreferrer noopener">least one prior line of therapy</a>.
Specialty Medicines sales grew by double-digit percentages (+10% and 15% cc) in the quarter to 3.33 billion pounds, reflecting continued growth across disease areas, with strong performances in HIV, Respiratory, Immunology &amp; Inflammation, and Oncology. General Medicines sales fell by 10% (-6% cc) to 2.57 billion pounds.
GSK is progressing on 14 major pipeline opportunities, each with a potential value of over 2 billion pounds, set to launch between 2025 and 2031.
Phase 3 study for tebipenem, a new antibiotic for complicated urinary tract infections, was stopped early because it worked so well. The company plans to file for approval by the end of the year. Phase 3 development for depemokimab, aimed at treating COPD, has begun with the launch of the ENDURA study program.
Key trials expected to begin in the second half of 2025 include GSK&#8217;227, a B7H3-targeting antibody-drug conjugate for small cell lung cancer, GSK&#8217;981 (IDRx-42) for second-line treatment of gastrointestinal stromal tumors, Efimosfermin for MASH, and an ultra-long-acting injectable HIV treatment combining cabotegravir and rilpivirine, to be given every four months.
<h2 class="wp-block-heading">Tariff Outlook and Guidance</h2>
Addressing a broader macroeconomic concern, GSK acknowledged the U.S. Administration&#8217;s initiation of an investigation under Section 232 of the Trade Expansion Act, which seeks to ascertain the potential effects of <a href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline">pharmaceutical product imports</a> on national security. 
The company said it is well-positioned to respond to the potential financial impact of tariffs, with mitigation options identified. According to Reuters, GSK&#8217;s CFO indicated an anticipation of some tariffs coming in the second half of the year, which are expected to lower the gross margin slightly.
GSK raised its full-year 2025 guidance and says it includes tariffs enacted thus far and the European tariffs indicated this week. It now expects sales to increase toward the <a href="https://www.benzinga.com/general/biotech/25/04/45100064/britains-gsk-asserts-it-is-well-positioned-to-mitigate-potential-tariffs-after-strong-q1-cancer-and-hiv-drug-sales" target="_blank" rel="noreferrer noopener">top of the 3%–5% range</a>.
Core operating profit and earnings are also expected to grow towards the top end of the 6% to 8% range. Specialty Medicine sales are expected to increase in the low teens versus prior guidance of a low double-digit percentage.
Vaccine revenue is expected to decline by a low single-digit percent to broadly stable compared to the prior outlook of a decrease of low single-digit percent, and general medicine sales are expected to be broadly stable.
Price Action:&nbsp;At last check on Wednesday, GSK stock was up 3.57% to $40.37 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46716995/novo-nordisk-charts-signal-weakness-amid-wegovy-warning-expert-says-couldve-played-out-very-differently-if-they-had-embraced-hims" target="_blank" rel="noreferrer noopener">Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says &#8216;Could&#8217;ve Played Out VERY Differently If They Had Embraced $HIMS&#8217;</a></li>
</ul>
Photo by HJBC via Shutterstock

Biotech

Earnings

Large Cap

Health Care

General

GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth

Evercore ISI Group analyst Jonathan Chappell maintains Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) with a Underperform and raises the price target from $21 to $25.

WERN

Evercore ISI Group Maintains Underperform on Werner Enterprises, Raises Price Target to $25

Martı, Turkey's leading ride-hailing platform, has committed 20% of its <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46681312/trumps-bitcoin-reserve-just-legitimized-it-coinbase-ceo-brian-armstrong-says-g20-nations-now-rushing-to-build-their-own-btc-stockpiles">cash reserves to crypto assets</a>, starting with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), CEO Oğuz Alper Öktem announced on Wedjesday.
The move positions Martı among a growing list of global companies incorporating digital assets into their treasury management strategies.
"We view digital assets as a long-term store of value," Öktem <a href="https://x.com/OguzAlperOktem/status/1950169167409119303">said</a>. "Our aim is to preserve the purchasing power of cash that is not allocated to operational spending." He also emphasized that Martı&#8217;s core transportation operations and growth plans remain fully funded and unaffected by the crypto allocation.
Martı becomes the first prominent Turkish mobility company to publicly announce Bitcoin holdings as part of its treasury policy. 
The decision reflects broader institutional interest in Bitcoin as a hedge against inflation and currency debasement.
Martı's decision mirrors actions taken by several high-profile companies globally. 
Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) has been the most aggressive corporate Bitcoin buyer, holding over 628,000 BTC as of July 2025, acquired through a <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46706233/strategy-closes-2-52b-strc-ipo-acquires-21021-bitcoin-at-117k-each">mix of equity and debt raises.</a>
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46683578/chinese-bitcoin-mining-tech-producer-bitmain-is-betting-big-on-america-but-why">Chinese Bitcoin Mining Tech Producer Bitmain Is Betting Big On America—But Why?</a>
Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) also purchased $1.5 billion worth of Bitcoin in 2021 and held portions on its balance sheet through subsequent years.
Other firms like Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) and Coinbase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) have included Bitcoin in their reserves, citing similar long-term value arguments. 
More recently, companies such as Sharplink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) and BTCS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) have added Bitcoin to their treasuries and publicly reported these holdings in regulatory filings.
The trend has gained momentum as Bitcoin ETF approvals, institutional custody solutions, and favorable accounting standards reduce perceived risks around crypto treasury exposure.
Founded in 2018, Martı operates Turkey's largest app-based mobility platform, offering shared scooters, e-mopeds, and ride-hailing services in urban areas. 
As a publicly listed company on the New York Stock Exchange, Martı's Bitcoin allocation adds transparency and weight to its treasury policy shift.
The firm has not disclosed the total value of its cash reserves or the exact volume of Bitcoin purchased, but the 20% figure signals a strategic pivot in how Martı manages idle liquidity under varied macroeconomic conditions.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46669857/meme-coins-reflect-crypto-market-maturation-says-drift-protocols-cindy-leow">Meme Coins Reflect Crypto Market Maturation, Says Drift Protocol&#8217;s Cindy Leow</a></li>
</ul>
Image: Shutterstock

$BTC

BTCS

COIN

MSTR

SBET

'Turkey's Uber' Joins Strategy, Tesla As Bitcoin Treasury Company

Nuvve Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>), a global leader in vehicle-to-grid (V2G) technology and grid modernization, today announced that its Board of Directors has approved the initial purchase of up to $3 million in Hype tokens, reflecting the company's continued commitment to blockchain-enabled infrastructure, and its belief in the transformative potential of the Hype ecosystem.
"This move is not just about crypto, it's about where our industry is going and how Nuvve intends to lead it," said Gregory Poilasne, CEO of Nuvve. "The Hype blockchain offers real-world applications that align with our roadmap and global expansion including but not limited to the smart energy ecosystem."
DeFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEFT#NASDAQ">DEFT</a>) (CBOE CA: DEFI) (GR: R9B)announced last week it will manage Nuvve's HYPE treasury strategy through its newly launched DeFi Advisory business line. This marks the first step in a bold new blockchain-driven growth initiative.
The strategic investment aligns with Nuvve's broader business objectives and is supported by the company's recently filed $300 million shelf registration. In addition to enhancing Nuvve's treasury strategy, the company views the integration of Hype blockchain as a long-term driver of innovation and value creation across a variety of applications including energy.

DEFT

NVVE

Nuvve Approves Initial Investment Of Up To $3M In Hype Tokens To Drive Blockchain-Powered Smart Energy Innovation

Terreno Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>), an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, sold an industrial property located in Tukwila, Washington on July 28, 2025 for a sale price of approximately $9.5 million.
The property consists of a 2.1-acre improved land parcel which is 100% leased. The property was purchased by Terreno Realty Corporation on December 30, 2020 for $6.6 million. The unleveraged internal rate of return generated by the investment was 10.3%.
Terreno Realty Corporation acquires, owns and operates industrial real estate in six major coastal U.S. markets: New York City/Northern New Jersey; Los Angeles; Miami; San Francisco Bay Area; Seattle; and Washington, D.C.

TRNO

Terreno Realty Sells Industrial Property In Tukwila, Washington For ~$9.5M

Evercore ISI Group analyst Steve Sakwa maintains Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) with a In-Line and raises the price target from $162 to $175.

WELL

Evercore ISI Group Maintains In-Line on Welltower, Raises Price Target to $175

Keybanc analyst Eric Heath maintains CommVault Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) with a Overweight and raises the price target from $195 to $225.

CVLT

Keybanc Maintains Overweight on CommVault Systems, Raises Price Target to $225

Illumina TruSight&#x2122; Oncology 500 v2 research assay is now available with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input
Illumina's growing research and clinical oncology portfolio broadens access to critical biomarker testing
SAN DIEGO, July 30, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) today announced the launch of the next generation of TruSight Oncology 500, its flagship cancer research assay that enables comprehensive genomic profiling. Comprehensive genomic profiling (CGP) is a critical tool to accelerate access to precision medicine by providing a molecular tumor profile to labs advancing research in therapy selection and clinical trial eligibility. TruSight Oncology 500 version 2 (TSO 500 v2)&nbsp;offers a streamlined sample-to-analysis workflow and reflects Illumina's commitment to serving customers with the highest quality and most rigorously tested solutions.

ILMN

Illumina Launches TruSight Oncology 500 v2 With Built-In HRD Detection, Faster Results, And Lower Sample Requirements For Advanced Cancer Research

Press Releases

Sharps Technology Announces Reverse Stock Split

Contracts

Sharps Technology Secures $400K Initial Purchase Order from U.S. Leader in IV Flushing Solutions as Part of $50 Million SoloGard Supply Agreement

Financing

Sharps Technology Receives ~$100K Initial Purchase Order from Hungarian Vaccine Provider for SecureGard™ Syringes

Sharps Technology to Present at the Aegis Capital Corp. 2025 Virtual Conference on May 22nd

Sharps Technology Regains Compliance with Nasdaq Minimum Bid Price Listing Rule

Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements

Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025

Life Sciences Investor Forum Agenda Announced for June 11th-12th

Life Sciences Investor Forum: Now Available for Online Viewing

Sharps Technology Advances Shipment Under $50 Million SoloGard Supply Agreement and Begins Manufacturing Facility Upgrades

ADIA

ATNM

BPTH

CNVIF

COCH

CSLLY

IMNN

MTVA

NIKA

PYNKF

SDZNY

SPHRY

STSSW

TIVC

TSXV:CNVI

TSXV:PINK

VYCO

Advanced Biomed

Cuprina Holdings (Cayman) Limited - Ordinary shares

Cuprina Holdings (Cayman)

Innovative Eyewear

Meihua International Medical Technologies Co., Ltd. - Ordinary Shares

Meihua Intl Medical Techs

InspireMD

NexGel

Rockwell Medical

Retractable Technologies, Inc. Common Stock

Retractable Technologies

TELA Bio

VolitionRX

WORK Medical Technology Group LTD - Class A Ordinary Shares

WORK Medical Tech Gr

Xtant Medical Holdings, Inc. Common Stock

Xtant Medical Hldgs

Aegis Capital

Screenshot 2024-04-02 at 6.12.50 PM

Sharps Technology&#39;s Global Expansion: Achieving Key Milestones To Strengthen Market Position

Comments

Sharps Technology

Sharps Technology (STSS) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL